COVID-19 outcomes in haemopoietic stem cell transplant recipients in Western Australia: the value of vaccination and antiviral therapy

Jacques A.J. Malherbe; Peter Boan; Duncan Purtill; Matthew Wright; Paul Cannell; Shane A. Gangatharan; Hasib Sidiqi; Julian Cooney

doi:10.1111/imj.16368

COVID-19 outcomes in haemopoietic stem cell transplant recipients in Western Australia: the value of vaccination and antiviral therapy

Jacques A.J. Malherbe, Peter Boan, Duncan Purtill, Matthew Wright, Paul Cannell, Shane A. Gangatharan, Hasib Sidiqi, Julian Cooney

Research output: Contribution to journal › Article › peer-review

Abstract

Coronavirus-19 (COVID-19) mortality rates among haemopoietic stem cell transplant (HSCT) patients are high, ranging between 20% and 40%. We prospectively evaluated the mortality outcomes of COVID-19 in Western Australian HSCT patients. A total of 32/492 (6.5%) HSCT recipients contracted COVID-19 during the study, of whom 30/32 (94%) developed mild or asymptomatic disease. Two allogeneic HSCT patients were hospitalised for severe COVID-19; one patient died. Stringent healthcare, social isolation practices, aggressive vaccination programmes and rapid access to COVID-19 antivirals may have promoted mild COVID-19 illness in Western Australian HSCT patients, resulting in one of the lowest COVID-19 mortality rates in HSCT recipients worldwide.

Original language	English
Pages (from-to)	664-670
Number of pages	7
Journal	Internal Medicine Journal
Volume	54
Issue number	4
Early online date	4 Apr 2024
DOIs	https://doi.org/10.1111/imj.16368
Publication status	Published - Apr 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/imj.16368Licence: CC BY-NC

Cite this

@article{909251748cd742b6aa90561885f87da5,

title = "COVID-19 outcomes in haemopoietic stem cell transplant recipients in Western Australia: the value of vaccination and antiviral therapy",

abstract = "Coronavirus-19 (COVID-19) mortality rates among haemopoietic stem cell transplant (HSCT) patients are high, ranging between 20% and 40%. We prospectively evaluated the mortality outcomes of COVID-19 in Western Australian HSCT patients. A total of 32/492 (6.5%) HSCT recipients contracted COVID-19 during the study, of whom 30/32 (94%) developed mild or asymptomatic disease. Two allogeneic HSCT patients were hospitalised for severe COVID-19; one patient died. Stringent healthcare, social isolation practices, aggressive vaccination programmes and rapid access to COVID-19 antivirals may have promoted mild COVID-19 illness in Western Australian HSCT patients, resulting in one of the lowest COVID-19 mortality rates in HSCT recipients worldwide.",

keywords = "antiviral, bone marrow transplant, COVID-19, vaccination",

author = "Malherbe, {Jacques A.J.} and Peter Boan and Duncan Purtill and Matthew Wright and Paul Cannell and Gangatharan, {Shane A.} and Hasib Sidiqi and Julian Cooney",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.",

year = "2024",

month = apr,

doi = "10.1111/imj.16368",

language = "English",

volume = "54",

pages = "664--670",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "John Wiley & Sons",

number = "4",

}

TY - JOUR

T1 - COVID-19 outcomes in haemopoietic stem cell transplant recipients in Western Australia

T2 - the value of vaccination and antiviral therapy

AU - Malherbe, Jacques A.J.

AU - Boan, Peter

AU - Purtill, Duncan

AU - Wright, Matthew

AU - Cannell, Paul

AU - Gangatharan, Shane A.

AU - Sidiqi, Hasib

AU - Cooney, Julian

PY - 2024/4

Y1 - 2024/4

N2 - Coronavirus-19 (COVID-19) mortality rates among haemopoietic stem cell transplant (HSCT) patients are high, ranging between 20% and 40%. We prospectively evaluated the mortality outcomes of COVID-19 in Western Australian HSCT patients. A total of 32/492 (6.5%) HSCT recipients contracted COVID-19 during the study, of whom 30/32 (94%) developed mild or asymptomatic disease. Two allogeneic HSCT patients were hospitalised for severe COVID-19; one patient died. Stringent healthcare, social isolation practices, aggressive vaccination programmes and rapid access to COVID-19 antivirals may have promoted mild COVID-19 illness in Western Australian HSCT patients, resulting in one of the lowest COVID-19 mortality rates in HSCT recipients worldwide.

AB - Coronavirus-19 (COVID-19) mortality rates among haemopoietic stem cell transplant (HSCT) patients are high, ranging between 20% and 40%. We prospectively evaluated the mortality outcomes of COVID-19 in Western Australian HSCT patients. A total of 32/492 (6.5%) HSCT recipients contracted COVID-19 during the study, of whom 30/32 (94%) developed mild or asymptomatic disease. Two allogeneic HSCT patients were hospitalised for severe COVID-19; one patient died. Stringent healthcare, social isolation practices, aggressive vaccination programmes and rapid access to COVID-19 antivirals may have promoted mild COVID-19 illness in Western Australian HSCT patients, resulting in one of the lowest COVID-19 mortality rates in HSCT recipients worldwide.

KW - antiviral

KW - bone marrow transplant

KW - COVID-19

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=85189985076&partnerID=8YFLogxK

U2 - 10.1111/imj.16368

DO - 10.1111/imj.16368

M3 - Article

C2 - 38572768

AN - SCOPUS:85189985076

SN - 1444-0903

VL - 54

SP - 664

EP - 670

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 4

ER -

COVID-19 outcomes in haemopoietic stem cell transplant recipients in Western Australia: the value of vaccination and antiviral therapy

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this